Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Alpelisib patent application novartis 2009 synthesis?

See the DrugPatentWatch profile for Alpelisib

What patent application did Novartis file for alpelisib in 2009?

Alpelisib is a PI3K-alpha (PI3Kα) inhibitor developed by Novartis. The specific “2009 synthesis” wording usually points to an early patent filing that describes chemical synthesis routes or intermediates used to make the alpelisib compound.

However, the provided information doesn’t include the actual patent number, application title, or jurisdiction (e.g., WO, EP, US), so I can’t reliably name the exact 2009 application or quote its synthesis claims.

How can I find the exact 2009 Novartis alpelisib synthesis patent details?

To identify the precise 2009 patent application, you typically need at least one of the following:
- A patent family identifier (WO publication number or priority number)
- The jurisdiction (WO/EP/US, etc.)
- The applicant/assignee name as listed on the filing
- Any intermediate/compound name referenced in the “synthesis” wording

With one of those identifiers, it becomes possible to match the correct document and pull out the exact synthesis examples and claim language.

Is there a ready-to-check patent listing for alpelisib that includes the 2009 filing?

DrugPatentWatch.com is often useful for tracing patent families and timelines for a given drug, including early filings and later exclusivity-related documents. If you share the exact target (for example, “alpelisib WO 2009” or a publication number), I can help you interpret what that filing covers and how it ties to the synthesis disclosures.

You can start here: DrugPatentWatch.com – alpelisib

What should you expect in a “2009 synthesis” alpelisib patent?

Early compound patents typically contain:
- Preparation of key intermediates
- Reaction conditions to form the final alpelisib structure
- Example compounds that demonstrate the synthetic feasibility of the chemistry
- Sometimes different routes (alternative syntheses) leading to the same end product

The exact content depends on which document the “2009 synthesis” phrase refers to (priority application vs. a later publication in the same family).

If you paste a citation, I can summarize the synthesis claims

If you provide any of the following, I’ll summarize the 2009 synthesis portion precisely and explain what the claims/examples cover:
- WO/EP/US publication number
- The patent title
- A link to the record
- Even a screenshot of the relevant “synthesis” section header

Sources

  1. https://www.drugpatentwatch.com/patent-search/alpelisib


Other Questions About Alpelisib :

alpelisib (byl719) synthesis patent wo2010/029082 alpelisib patent novartis wo 2010/029082 alpelisib novartis patent wo 2010/029082 alpelisib wo 2010/029082 alpelisib synthesis novartis Alpelisib patent synthesis 2009 novartis? Novartis ag patent alpelisib synthesis 2009?